Flowable matrix compositions and methods
First Claim
Patent Images
1. A soft tissue matrix composition for use in a patient treatment, the composition consisting of:
- a cryofractured human soft tissue material having a mechanically disrupted extracellular matrix collagen or macrostructure and a partially disrupted collagen microfibrillar architecture, wherein the cryofractured tissue material is in a hydrated state, the hydration comprising the natural interstitial water of the cryofractured soft tissue material that is present prior to cryofractionation; and
a wetting agent, wherein the wetting agent is at least one wetting agent selected from the group consisting of water, saline solution, phosphate buffered saline (PBS), sodium dodecyl sulfate, sodium stearate, benzalkonium chloride, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), lecithin, (p-t-Octylphenoxy)polyethoxyethanol, and nonoxynol-9.
1 Assignment
0 Petitions
Accused Products
Abstract
Flowable matrix compositions and methods of their use and manufacture are provided. Exemplary compositions may include a flowable, syringeable, putty-like form of acellular human dermal matrix. In some cases, compositions may include a moldable acellular collagen extracellular matrix. In use, the matrix compositions can be used to fill or treat skin voids, channel wounds, and other soft tissue deficiencies.
232 Citations
68 Claims
-
1. A soft tissue matrix composition for use in a patient treatment, the composition consisting of:
- a cryofractured human soft tissue material having a mechanically disrupted extracellular matrix collagen or macrostructure and a partially disrupted collagen microfibrillar architecture, wherein the cryofractured tissue material is in a hydrated state, the hydration comprising the natural interstitial water of the cryofractured soft tissue material that is present prior to cryofractionation; and
a wetting agent, wherein the wetting agent is at least one wetting agent selected from the group consisting of water, saline solution, phosphate buffered saline (PBS), sodium dodecyl sulfate, sodium stearate, benzalkonium chloride, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), lecithin, (p-t-Octylphenoxy)polyethoxyethanol, and nonoxynol-9. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)
- a cryofractured human soft tissue material having a mechanically disrupted extracellular matrix collagen or macrostructure and a partially disrupted collagen microfibrillar architecture, wherein the cryofractured tissue material is in a hydrated state, the hydration comprising the natural interstitial water of the cryofractured soft tissue material that is present prior to cryofractionation; and
-
35. A soft tissue matrix composition for use in a patient treatment, the composition consisting of:
- a cryofractured and triturated human soft tissue material having a mechanically disrupted extracellular matrix collagen or macrostructure and a partially disrupted collagen microfibrillar architecture, wherein the cryofractured and triturated tissue material is in a hydrated state, the hydration comprising the natural interstitial water of the cryofractured and triturated human soft tissue material that is present prior to cryofractionation and trituration; and
a wetting agent, wherein the wetting agent is at least one wetting agent selected from the group consisting of water, saline solution, phosphate buffered saline (PBS), sodium dodecyl sulfate, sodium stearate, benzalkonium chloride, 3-[(3-cholamidopropyl)dimetylammonio]-1-propanesulfonate (CHAPS), lecithin, (n-t-Octylphenoxy)polyethoxyethanol, and nonoxynol-9. - View Dependent Claims (36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)
- a cryofractured and triturated human soft tissue material having a mechanically disrupted extracellular matrix collagen or macrostructure and a partially disrupted collagen microfibrillar architecture, wherein the cryofractured and triturated tissue material is in a hydrated state, the hydration comprising the natural interstitial water of the cryofractured and triturated human soft tissue material that is present prior to cryofractionation and trituration; and
Specification